NASDAQ
88.31USD
-1.40 (-1.56%)
We have scored 14 news catalysts on Mirum Pharmaceuticals, Inc. (MIRM) over the past 12 months. The biggest single-day move next to one of them came Jul 4, 2026, when MIRM closed +4.3%: “Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio”. Coverage across the window leans positive (average ticker sentiment +0.64). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.4B
P/E
—
EPS
—
Beta
0.49
52W range
63.23-130
Day range
84.89–90.00
Open
90.00
Prev close
89.70
Volume
697.9K
Avg volume
770.7K
Dividend
0.00
IPO
2019-07-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Mirum Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MIRM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
